An efficient synthesis of aryldifluoromethyl aryl ethers was established via nickel-catalyzed aryloxydifluoromethylation. Using this protocol, difluoromethylated PD-1/PD-L1 immune checkpoint inhibitors were comveniently achieved with enhanced antitumor efficacy over the non-fluoro congeners.